Targeting the N1DARP–N1ICD interaction and N1ICD degradation could be a promising alternative strategy for treating Notch1-activated pancreatic cancer and may have broader applications in the treatment of non-cancerous diseases. Here, NOTCH1 is linked to pancreatic neoplasm.